Boehringer Ingelheim: all 2,305 studies
Page 14 of 24. Open to participants first (62), then studies with results posted, then the rest; newest registration first within each.
- A Study in Healthy Men to Test How Different Doses of BI 1584862 Are Tolerated and How BI 1584862 is Taken up in the Body With or Without FoodCompletedNCT05520827Phase 1
- A Study in Healthy Men to Test How Different Doses of BI 3032950 Are ToleratedCompletedNCT05518708Phase 1
- A Study in Healthy Men to Test How BI 690517 is Taken up and Handled by the BodyCompletedNCT05515588Phase 1
- A Study in Healthy Men to Test How BI 685509 is Processed in the BodyCompletedNCT05515328Phase 1
- Correlation Between Changes in Lung Function and Changes in Cough and Dyspnoea in Nintedanib-treated Connective Tissue Disease Interstitial Lung Disease (CTD-ILD) PatientsTerminatedNCT05503030
- A Study to Test Different Imaging Techniques in Patients With Different Types of Interstitial Lung DiseaseCompletedNCT05492994Not applicable
- A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are ToleratedCompletedNCT05469646Phase 1
- A Study in Healthy Men to Test How Esomeprazole Influences the Amount of BI 1819479 in the BloodCompletedNCT05467475Phase 1
- A Study in Healthy Men to Test Whether BI 474121 Can Reverse the Memory Problems Caused by KetamineWithdrawnNCT05451095Phase 1
- A Study to Test How Healthy Women Tolerate Different Doses of BI 1819479CompletedNCT05440799Phase 1
- A Study in Healthy Men to Test How BI 456906 is Processed in the BodyCompletedNCT05421338Phase 1
- A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called GlioblastomaCompletedNCT05376800Phase 1
- A Study in People With Advanced Cancer to Test Whether the Amount of BI 907828 in the Blood is Influenced by Taking an OATP Inhibitor or a CYP3 InhibitorCompletedNCT05372367Phase 1
- A Study in Healthy Men to Test How Well Different Doses of BI 1839100 Are Tolerated (1490-0001)CompletedNCT05354453Phase 1
- A Study in Healthy Men to Test How Different Doses of BI 1815368 Are Tolerated and How BI 1815368 is Taken up in the Body With or Without FoodCompletedNCT05337592Phase 1
- A Study in People With Advanced Cancer to Test How Well Different Doses of BI 770371 Alone or in Combination With Ezabenlimab Are ToleratedActive, not recruitingNCT05327946Phase 1
- A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906CompletedNCT05296733Phase 1
- A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver CancerCompletedNCT05249426Phase 1
- A Study to Test Whether Different Doses of BI 1291583 Help People With BronchiectasisCompletedNCT05238675Phase 2
- A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the LiverActive, not recruitingNCT05202353Phase 1
- A Study in Healthy Japanese Men to Test How Well Different Doses of BI 1291583 Are ToleratedCompletedNCT05183347Phase 1
- A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)SuspendedNCT05155332Phase 1
- A Study to Test How Well Healthy Men Tolerate BI 765250 When Given as an Infusion Into the Vein or as an Injection Under the SkinCompletedNCT05151653Phase 1
- INCHANGE - Nintedanib for Changes in Cough and Dyspnea in Patients Suffering From Chronic Fibrosing Interstitial Lung Disease With a Progressive Phenotype in Everyday Clinical Practice: a Real-world EvaluationCompletedNCT05151640
- Afatinib (GILOTRIF®) in Patients Suffering From Tumors Harboring Neuregulin 1 (NRG1) Gene Alterations (Specifically NRG1 Gene Fusion-positive Advanced Solid Tumors)No longer availableNCT05107193
- Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line SulfonylureasWithdrawnNCT05102071
- A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking EzabenlimabActive, not recruitingNCT05068102Phase 1
- A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS MutationActive, not recruitingNCT04973163Phase 1
- A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck CancerActive, not recruitingNCT04958239Phase 1
- A Study in Healthy Men to Find the Best Formulation of BI 685509 and to Test How it is Taken up in the BodyCompletedNCT04926246Phase 1
- A Study in Men With Overweight to Test How Well Different Doses of BI 1820237 Are Tolerated When Given as an Injection Alone or in Combination With LiraglutideCompletedNCT04903509Phase 1
- A Study to Test Whether BI 767551 Can Prevent COVID-19 in People Who Have Been Exposed to SARS-CoV-2WithdrawnNCT04894474Phase 2/3
- A Trial in Healthy Men and Women to Find Out How Well Different Doses of BI 1291583 Are ToleratedCompletedNCT04866160Phase 1
- A Study to Find a Safe and Effective Dose of BI 1701963 Alone and in Combination With BI 3011441 in Patients With Advanced Cancer and a Certain Mutation (Kirsten Rat Sarcoma Viral Oncogene Homologue [KRAS])TerminatedNCT04835714Phase 1
- A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated and Taken up by the Body With or Without FoodCompletedNCT04801693Phase 1
- A Study Evaluating Different Doses of BI 765049 When Given Alone and When Given With Ezabenlimab to Patients With Advanced Solid Tumors Expressing the Protein B7-H6 on the Cell SurfaceCompletedNCT04752215Phase 1
- An Expanded Access Program in Belgium to Provide Nintedanib to People With Lung Diseases Called Non-IPF ILDs Who Have no Alternative Treatment OptionsNo longer availableNCT04739150
- A Study to Test Different Doses of BI 730357 and Find Out Whether They Reduce Symptoms in People With Active Psoriatic ArthritisWithdrawnNCT04680676Phase 2
- A Study in Healthy Japanese Men to Test How Well Different Doses of BI 764198 Are ToleratedCompletedNCT04665700Phase 1
- A Study in Healthy Men to Test if Different Formulations of BI 764198 With or Without Food Influence the Amount of BI 764198 in the BloodCompletedNCT04656288Phase 1
- A Study to Test Different Doses of BI 765063 Alone and in Combination With BI 754091 in Japanese Patients With Different Types of Advanced Cancer (Solid Tumors)CompletedNCT04653142Phase 1
- A Study to Test Different Doses of BI 1701963 in Combination With Irinotecan in People With Advanced Bowel Cancer With Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) MutationTerminatedNCT04627142Phase 1
- NICEFIT-ON: A Study Under Routine Clinical Practice in Taiwan to Observe the Long-term Outcome of People With Certain Types of Lung Disease (PF-ILD, SSc-ILD, IPF) Who Start Treatment With NintedanibCompletedNCT04614441
- A Study to Test BI 754091 Alone or in Combination With BI 836880 in People Who Have Advanced Anal CancerWithdrawnNCT04499352Phase 2
- A Study to Test How Well Different Doses of BI 1356225 Are Tolerated by Men and Women With Obesity or OverweightCompletedNCT04447261Phase 1
- A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3Active, not recruitingNCT04429087Phase 1
- Tiotropium Plus Olodaterol vs Inhaled Corticosteroids (ICS) Regimens in the Portuguese Primary Care Setting (TIOLCOR Study)WithdrawnNCT04402515
- A Study to Test How Different Doses of BI 456906 Are Tolerated in Japanese Men With a Body Mass Index (BMI) Between 23 and 40 kg/m2CompletedNCT04384081Phase 1
- Post-marketing Surveillance on Long Term Use of Ofev Capsules in Systemic Scleroderma Associated Interstitial Lung Disease (SSc-ILD) in JapanCompletedNCT04325217
- TARA Working Prototype [Version 2]: Feasibility StudyWithdrawnNCT04320524Not applicable
- Real-world Study Comparing the Adherence and Effectiveness of Linagliptin vs. AcarboseTerminatedNCT04180813
- A Study in People With Normal Kidney Function and People With Reduced Kidney Function to Test How BI 764198 is Processed in the BodyCompletedNCT04176536Phase 1
- A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)Active, not recruitingNCT04111458Phase 1
- A Study to Test How Well Healthy Men Tolerate Different Doses of BI 764198CompletedNCT04102462Phase 1
- TARA Working Prototype Engagement Evaluation: Feasibility StudyCompletedNCT04085302Not applicable
- A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225CompletedNCT04065295Phase 1
- A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab)CompletedNCT03964233Phase 1
- A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1291583 in the BloodCompletedNCT03890887Phase 1
- A Study in Healthy Men and Women to Find Out How Well Different Doses of BI 1291583 Are ToleratedTerminatedNCT03868540Phase 1
- A Study in Healthy Men Tests How Different Doses of BI 764198 Are Taken up in the Body and How Well They Are Tolerated.CompletedNCT03854552Phase 1
- An Expanded Access Program to Provide Nintedanib to Patients With Non-IPF ILD Who Have no Alternative Treatment PossibilitiesApproved for marketingNCT03843892
- A Study to Test How Different Doses of BI 685509 Are Tolerated in Patients With Liver ProblemsCompletedNCT03842761Phase 1
- A Study to Test How Food Influences the Amount of BI 1291583 in the Blood of Healthy MenCompletedNCT03837964Phase 1
- BI 705564 in Patients With Systemic Lupus Erythematosus (SLE)WithdrawnNCT03771885Phase 1
- This Study is Done in Healthy Japanese Volunteers. It Looks at How Different Doses of BI 705564 Are Taken up in the Body and How Well They Are ToleratedWithdrawnNCT03747926Phase 1
- A Study in Healthy Japanese Men to Test How Different Doses of BI 690517 Are Taken Up in the Body and How Well They Are ToleratedCompletedNCT03608072Phase 1
- A Study to Test Different Doses of BI 456906 in Patients With ObesityCompletedNCT03591718Phase 1
- This Study Aims to Find the Best Dose of BI 907828 (Brigimadlin) in Patients With Different Types of Advanced Cancer (Solid Tumors)CompletedNCT03449381Phase 1
- This Study Tests How Different Doses of BI 1291583 Are Taken up in the Body and How Well They Are ToleratedTerminatedNCT03414008Phase 1
- Comparative Effectiveness of Empagliflozin in the USCompletedNCT03363464
- This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With VenetoclaxWithdrawnNCT03343678Phase 1
- This Study Tests BI 685509 in Healthy Chinese and Japanese Men; the Study Tests How Different Doses of BI 685509 Are Taken up in the Body and How Well They Are ToleratedCompletedNCT03259464Phase 1
- This Study is Done in Healthy Chinese and Japanese Volunteers; it Looks at How BI 690517 is Taken up in the Body and How Well it is ToleratedCompletedNCT03206632Phase 1
- Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy in Real-world Japanese Therapeutic PracticeWithdrawnNCT03205137
- Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 456906 in Healthy Male VolunteersCompletedNCT03175211Phase 1
- This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are ToleratedCompletedNCT03165240Phase 1
- This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses)CompletedNCT03165227Phase 1
- Safety and Tolerability of BI 685509 in Healthy SubjectsCompletedNCT03116906Phase 1
- Drug-drug Interaction (DDI) With a P-gp Inhibitor, Organic Anion Transporting Polypeptide OATP-inhibitor, Food EffectCompletedNCT03116893Phase 1
- This Study Tests How Different Doses of BI 690517 Are Taken up in the Body of Healthy Men. The Study Also Looks at How Food Influences the Amount of BI 690517 in the BloodCompletedNCT03100916Phase 1
- Single Rising Dose Study of BI 690517 in Healthy VolunteersCompletedNCT02891148Phase 1
- Observational Study to Evaluate Safety of Idarucizumab in Pediatric PatientsWithdrawnNCT02798107
- Relative Bioavailability of BI 10773 Administered Twice Daily Compared BI 10773 Given Once Daily After Multiple Oral Doses in Healthy Male and Female VolunteersCompletedNCT02782624Phase 1
- fMRI in ImpulsivityCompletedNCT02755181
- Fingerprinting of ImpulsivityCompletedNCT02722174
- Olmutinib (BI 1482694) ADME StudyCompletedNCT02722161Phase 1
- A Study to Find a Safe Dose of Volasertib Given in Addition to Standard Salvage Chemotherapy in Children (Age 3 Months to Less Than 18 Years) With Acute Myeloid Leukaemia, in Whom Front-line Chemotherapy FailedWithdrawnNCT02722135Phase 1
- Investigation of Single Rising Doses of BI 685509CompletedNCT02694354Phase 1
- Relative Bioavailability of Two Newly Developed Tablet Formulations (TF2 and iFF)Compared to BI 1060469 TF1 Formulation, Following Oral Administration (Low and High Dose)in Healthy Female SubjectsCompletedNCT02438696Phase 1
- VARGADO - Vargatef in 2nd-line Therapy of Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02392455
- Effect of BI 1181181 on Midazolam, Warfarin, Omeprazole and DigoxinWithdrawnNCT02345304Phase 1
- The Effect of Multiple Doses of BI 187004 on the Single-dose Pharmacokinetics of Repaglinide and Bupropion in Healthy Male VolunteersCompletedNCT02305901Phase 1
- Study to Compare the Effect of a Combination of Dipyridamole With Sustained Release and Acetyl Salicylic Acid (Aggrenox®) on the Performance Relevant to Safety and on the General Condition of Healthy VolunteersCompletedNCT02278302Phase 1
- Bioequivalence of Telmisartan as Telmisartan 80 mg/HCTZ 12.5 mg Fixed-dose Combination Tablet or as Two Telmisartan 40 mg Tablets in Healthy Male VolunteersCompletedNCT02276391Phase 1
- Influence of Food on the Bioavailability of Two Doses of Telmisartan/HCTZ Fixed-dose Combination in Japanese Healthy Male VolunteersCompletedNCT02276378Phase 1
- Bioavailability of BI 10773 and Pioglitazone in Healthy Male VolunteersCompletedNCT02276365Phase 1
- Relative Bioavailability of Meloxicam 2 x 7.5 mg Tablets Compared to 15 mg Tablet and Dose Proportionality Over a Dose Range of 7.5 mg and 15 mg in Healthy VolunteersCompletedNCT02276352Phase 1
- Bioavailability of Dipyridamole of Asasantin p.o. in Three Experimental Formulations Relative to the Standard Formulation in Healthy Male SubjectsCompletedNCT02273557Phase 1
- Study to Evaluate Pharmacokinetics of Dipyridamole in Three New Formulations of Asasantin ER in Healthy Female and Male SubjectsTerminatedNCT02273544Phase 1
- Bioequivalence of a New Asasantin Formulation Extended Release (ER) Compared to the Commercially Available Asasantin Formulation (Aggrenox®; Extended Release) in Healthy Male and Female VolunteersCompletedNCT02273531Phase 1